IMVT insider ownership: who sold, why, and what they still hold

What stands out

Two insiders sold $9.0M with no disclosed plan: Andrew Fromkin ($7.4M) and Jay Stout ($1.5M). The filings don't state a reason.Andrew Fromkin: largest such sale, May 28, 2026 · Jay Stout: largest such sale, Jun 26, 2026

A share of stake is shown for 0 of the 10 officers and directors who sold. 14 are left out

Left out: Peter Salzmann, Frank Torti, Eva Barnett, Michael Geffner, Tiago Girao, Jay Stout, Melanie Gloria, Christopher Van Tuyl, Douglas Hughes, Atul Pande, Andrew Fromkin, Robert Susman, Jake Bauer and Eric Venker (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Andrew Fromkin

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.0M7% planned 93% no plan disclosed

Jay Stout

Chief Technology Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.4M35% to cover taxes 65% no plan disclosed

Melanie Gloria

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.7M59% to cover taxes 41% no plan disclosed

Christopher Van Tuyl

Chief Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.5M53% to cover taxes 47% no plan disclosed

Tiago Girao

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.4M73% to cover taxes 27% no plan disclosed

All 10 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Oct 7, 20263 executives sold 7.4K shares ($237K) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Jay Stout Chief Technology Officer	3,809	$32.06	n/a	n/a	Oct 7, 2026	Oct 9, 2026
Melanie Gloria Chief Operating Officer	2,241	$32.06	n/a	n/a	Oct 7, 2026	Oct 9, 2026
Christopher Van Tuyl Chief Legal Officer	1,327	$32.06	n/a	n/a	Oct 7, 2026	Oct 9, 2026

Oct 2, 2026Eric Venker sold 3.5K shares ($120K) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Eric Venker Chief Executive Officer, Director	3,506	$34.11	n/a	n/a	Oct 2, 2026	Oct 5, 2026

Sep 23, 2026Christopher Van Tuyl sold 2.8K shares ($103K) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Christopher Van Tuyl Chief Legal Officer	2,846	$36.36	n/a	n/a	Sep 23, 2026	Sep 25, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

Roivant Sciences Ltd. reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Immunovant, Inc. CEO selling stock?

No. Peter Salzmann reported no open-market sales in the past 12 months.

Why are Immunovant, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 8% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 26% were to cover taxes and 66% had no disclosed plan. A trading plan schedules sales in advance.

Are any Immunovant, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold10 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Andrew Fromkin Director	$8.0M 244K shares	Not confirmed share of stake is being verified. Why	7% under a disclosed plan 93% no plan disclosed
Jay Stout Chief Technology Officer	$2.4M 69K shares	Not confirmed share of stake is being verified. Why	35% to cover taxes 65% no plan disclosed
Melanie Gloria Chief Operating Officer	$1.7M 53K shares	Not confirmed share of stake is being verified. Why	59% to cover taxes 41% no plan disclosed
Christopher Van Tuyl Chief Legal Officer	$1.5M 45K shares	Not confirmed share of stake is being verified. Why	53% to cover taxes 47% no plan disclosed
Tiago Girao Chief Financial Officer	$1.4M 43K shares	Not confirmed share of stake is being verified. Why	73% to cover taxes 27% no plan disclosed
Eric Venker Chief Executive Officer, Director	$581K 21K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Atul Pande Director	$425K 12K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Douglas Hughes Director	$349K 15K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Robert Susman Director	$68K 2.5K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Michael Geffner Chief Medical Officer	$49K 2.6K shares	Not confirmed share of stake is being verified. Why	To cover taxes

Outside holder, reported separately: Roivant Sciences Ltd. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Peter Salzmann

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Peter Salzmann are complete.

Chief Executive Officer, Director

n/a

Vesting, gifts, unvested awards and holding lines for Peter Salzmann

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Salzmann are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
200,667	$30.78	Apr 2, 2034	$257K
374,395	$15.20	Apr 1, 2035	$6.3M

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Frank Torti

Director

n/a

Vesting, gifts, unvested awards and holding lines for Frank Torti

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Frank Torti are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,167	$30.78	Apr 2, 2034	$64K
93,599	$15.20	Apr 1, 2035	$1.6M
88,325	$24.61	Apr 7, 2036	$658K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Eva Barnett

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Eva Barnett

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eva Barnett are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
68,723	$30.78	Apr 2, 2034	$88K
125,180	$15.20	Apr 1, 2035	$2.1M

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Michael Geffner

Chief Medical Officer

n/a

−2.6K

n/a

Vesting, gifts, unvested awards and holding lines for Michael Geffner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Geffner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
150,000	$18.06	Jan 17, 2033	$2.1M
68,723	$30.78	Apr 2, 2034	$88K
143,063	$15.20	Apr 1, 2035	$2.4M

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Tiago Girao

Chief Financial Officer

n/a

−43K

n/a

Vesting, gifts, unvested awards and holding lines for Tiago Girao

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tiago Girao are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
283,505	$15.90	May 1, 2035	$4.6M
94,002	$24.61	Apr 7, 2036	$700K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Jay Stout

Chief Technology Officer

n/a

−69K

n/a

Vesting, gifts, unvested awards and holding lines for Jay Stout

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jay Stout are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
68,723	$30.78	Apr 2, 2034	$88K
107,297	$15.20	Apr 1, 2035	$1.8M
96,851	$24.61	Apr 7, 2036	$722K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Melanie Gloria

Chief Operating Officer

n/a

−53K

n/a

Vesting, gifts, unvested awards and holding lines for Melanie Gloria

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Melanie Gloria are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
137,446	$25.51	Nov 18, 2034	$900K
107,297	$15.20	Apr 1, 2035	$1.8M
121,063	$24.61	Apr 7, 2036	$902K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Christopher Van Tuyl

Chief Legal Officer

n/a

−45K

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Van Tuyl

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Van Tuyl are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
137,446	$27.63	Dec 16, 2034	$609K
53,707	$15.20	Apr 1, 2035	$906K
59,820	$24.61	Apr 7, 2036	$446K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Douglas Hughes

Director

n/a

−15K

n/a

Vesting, gifts, unvested awards and holding lines for Douglas Hughes

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Douglas Hughes are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,690	$30.78	Apr 2, 2034	$6K
7,600	$15.20	Apr 1, 2035	$128K
7,061	$24.61	Apr 7, 2036	$53K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Atul Pande

Director

n/a

−12K

n/a

Vesting, gifts, unvested awards and holding lines for Atul Pande

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Atul Pande are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,690	$30.78	Apr 2, 2034	$6K
7,600	$15.20	Apr 1, 2035	$128K
7,061	$24.61	Apr 7, 2036	$53K
270,252	$8.43	Nov 19, 2029	$6.4M
65,181	$8.43	Nov 19, 2029	$1.5M

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Andrew Fromkin

Director

n/a

−244K

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Fromkin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Fromkin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,690	$30.78	Apr 2, 2034	$6K
7,600	$15.20	Apr 1, 2035	$128K
7,061	$24.61	Apr 7, 2036	$53K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Robert Susman

Director

n/a

−2.5K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Susman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Susman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,234	$15.90	May 1, 2035	$569K
7,061	$24.61	Apr 7, 2036	$53K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Jake Bauer

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jake Bauer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jake Bauer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,234	$15.90	May 1, 2035	$569K
7,061	$24.61	Apr 7, 2036	$53K

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Eric Venker

Chief Executive Officer, Director

n/a

−21K

n/a

Vesting, gifts, unvested awards and holding lines for Eric Venker

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Venker are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,300,000	$16.76	Jul 28, 2035	$19.9M
189,900	$16.76	Jul 28, 2035	$2.9M
336,043	$24.61	Apr 7, 2036	$2.5M

Estimate: options held × ($32.06 − strike price), using the most recent insider trade price on Form 4 (Oct 7, 2026), not a market close.

Holdings and share of stake for Immunovant, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$16.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $16.3M across 505,861 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $1.4M · 8%

92%

The lighter segment is sales with no plan disclosed in the filing ($15.0M), including tax-related sales outside a plan.

No plan disclosed · $10.7M

Sales with no 10b5-1 plan and no tax reference in the filing. $7.4M of it is Andrew Fromkin. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Andrew Fromkin, May 28, 2026

Taxes

$5.1M of sales (31.4%) cite tax obligations in their footnotes, $866K of them also under a plan. Example: Christopher Van Tuyl, Oct 7, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Andrew Fromkin Director	244K	$8.0M	7%	49%	Dec 1, 2025 to May 28, 2026
Jay Stout Chief Technology Officer	69K	$2.4M	0%	14%	Oct 22, 2025 to Oct 7, 2026
Melanie Gloria Chief Operating Officer	53K	$1.7M	0%	10%	Nov 20, 2025 to Oct 7, 2026
Christopher Van Tuyl Chief Legal Officer	45K	$1.5M	0%	9%	Dec 18, 2025 to Oct 7, 2026
Tiago Girao Chief Financial Officer	43K	$1.4M	0%	9%	Apr 23, 2026 to Jul 23, 2026
Eric Venker Chief Executive Officer, Director	21K	$581K	0%	4%	Apr 2, 2026 to Oct 2, 2026
Atul Pande Director	12K	$425K	100%	3%	May 20, 2026 to Aug 28, 2026
Douglas Hughes Director	15K	$349K	100%	2%	Dec 1, 2025 to Dec 1, 2025
Robert Susman Director	2.5K	$68K	100%	0.4%	May 1, 2026 to May 1, 2026
Michael Geffner Chief Medical Officer	2.6K	$49K	0%	0.3%	Oct 22, 2025 to Oct 22, 2025

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$97K	$0	$97K	$0
Nov 2025	$298K	$0	$298K	$0
Dec 2025	$1.2M	$866K	$291K	$0
Jan 2026	$83K	$0	$83K	$0
Feb 2026	$90K	$0	$90K	$0
Mar 2026	$72K	$0	$72K	$0
Apr 2026	$1.8M	$0	$1.8M	$0
May 2026	$7.8M	$260K	$101K	$7.4M
Jun 2026	$3.5M	$108K	$93K	$3.3M
Jul 2026	$818K	$60K	$759K	$0
Aug 2026	$200K	$65K	$135K	$0
Sep 2026	$103K	$0	$103K	$0
Oct 2026	$356K	$0	$356K	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 2x the 5-year average. 10 insiders sold; the average is 6 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	506K	10	$16.3M
Oct 13, 2025 1 year earlier	202K	9	$4.2M
Oct 13, 2024 2 years earlier	325K	10	$10.5M
Oct 14, 2023 3 years earlier	472K	5	$9.7M
Oct 14, 2022 4 years earlier	293K	4	$2.1M
Oct 14, 2021 5 years earlier	0	0	$0

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Immunovant, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology357 filings on record, 53 filed in the 12-month period, and how we read them

All 357 Forms 3, 4 and 5 on record for Immunovant, Inc. (SEC CIK 1764013), filed from May 9, 2019 to Oct 9, 2026; 53 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (19)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
George Migausky	Apr 3, 2025	157,251 shares, last reported balance as of Apr 1, 2025
William Macias	Feb 21, 2025	357,353 shares, last reported balance as of Feb 19, 2025
Mark Levine	Nov 22, 2024	319,228 shares, last reported balance as of Nov 20, 2024
Julia Butchko	Aug 23, 2024	440,959 shares, last reported balance as of Aug 21, 2024
Rita Jain	Mar 31, 2021	129,365 shares, last reported balance as of Mar 19, 2021
Connealy Yanchik	Mar 23, 2021	46,200 shares, last reported balance as of Mar 19, 2021
Michael Elliott	Mar 23, 2021	97,600 shares, last reported balance as of Mar 19, 2021
Bradford Middlekauff	May 18, 2020	No balance on record
Health Sciences Holdings, LLC	Dec 20, 2019	2,875,000 shares, last reported balance as of May 9, 2019
Myrtle Potter	Dec 20, 2019	No balance on record
Robert Zeldin	Dec 20, 2019	No balance on record
Roderick Wong	Dec 13, 2019	902,498 shares, last reported balance as of Dec 11, 2019
Gotham Makker	May 9, 2019	20,000 shares, last reported balance as of May 9, 2019
Pedro Granadillo	May 9, 2019	20,000 shares, last reported balance as of May 9, 2019
Sukumar Nagendran	May 9, 2019	20,000 shares, last reported balance as of May 9, 2019
Mark Schoenebaum	May 9, 2019	20,000 shares, last reported balance as of May 9, 2019
Naveen Yalamanchi		No balance on record
Alice Lee		No balance on record
Stephanie Sirota		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Immunovant, Inc. insiders sold $16.3M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Immunovant, Inc. CEO selling stock?

Why are Immunovant, Inc. insiders selling?

Are any Immunovant, Inc. insiders buying?

The evidence

No plan disclosed · $10.7M

Taxes

Sales by month